NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Prosetta Biosciences

Prosetta Biosciences

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://prosetta.com/

Last Round

Series D

Dec 3, 2015

Est. Valuation

$20M

Total Funding Raised

$41.58M

Company Overview

Prosetta Biosciences is a biotechnology company that develops small-molecule antiviral therapeutics and advances drug discovery for oncology, neurodegenerative diseases, and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

drug discoverysmall-molecule therapeuticscell-free protein synthesisCFPSAprotein complex assemblybiotech R&Ddrug discovery platformantiviral drug developmentoncology researchneurodegenerative disease researchpreclinical developmentbiotech licensingmolecular homeostasisdrug discovery partnerwet-lab screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prosetta Biosciences Comps

Public and private peers based on sector, stage, and business model.

Prosetta Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Prosetta Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DDec 3, 2015
Series BJul 19, 2012
GrantJun 8, 2012
Series AMay 18, 2007

Key People

Founding team and executive leadership

Michael Farmer

President Co-CEO

Executive Team

Vishwanath R. Lingappa

CEO And CTO,

Executive Team

Prosetta Biosciences Investors

Notable investors and investment history

Prosetta Biosciences investors
InvestorRounds
U.S. Department of Health and Human ServicesGrant
AlgerSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 8, 2012

    $442K grant from U.S. Department of Health and Human Services

Prosetta Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Prosetta Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Prosetta Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range23
Year Founded2003
Last FundingDec 3, 2015

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.